Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - EKIMAS Corp | asnb8k_ex99z1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 6, 2020 (April 6, 2020)
EKIMAS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware |
| 001-11737 |
| 04-3186647 |
(State or Other Jurisdiction of Incorporation) |
| (Commission File Number) |
| (IRS Employer Identification No.) |
95 Washington Street #154, Canton, Massachusetts |
| 02021 |
(Address of principal executive offices) |
| (Zip Code) |
Issuer’s telephone number (508) 523-3141
ADVANSOURCE BIOMATERIALS CORPORATION
229 Andover Street, Wilmington, Massachusetts 01887
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Common Stock, par value $0.001 per share |
| ASNB |
| Not applicable |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On April 6, 2020, EKIMAS Corporation (formerly known as AdvanSource Biomaterials Corporation) (the “Company”), announced that the Company’s Board of Directors approved a special cash distribution of $0.18 per share at its April 3, 2020 meeting. The cash distribution is payable on April 23, 2020 to shareholders of record as of April 16, 2020. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
Exhibit No. |
| Description |
99.1 |
| Press Release Announcing Special Cash Distribution, dated April 6, 2020 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| EKIMAS CORPORATION |
|
|
Dated: April 6, 2020 | /s/ Michael F. Adams |
| Michael F. Adams |
| President and Chief Executive Officer |